Replies to post #3 on ChemGenex Pharmaceuticals, Ltd. (fkx ASX:CXS)

[wbart21]

Before Year end
1)EU Deal
2)MAA Filing
3)AHA Data/Pres.
4)FDA decision on priority review

Co's stated intent is to use $$ from EU Deal to underwrite US launch in Q2(assuming priority review and approval). I do not believe the European market for T315i is very large(thankfully).There will be off-label and line extension potential,but any guesses as to value/terms of the upcoming EU deal ? I hope it is large enough to avoid further dilution($50mm+ upfront).
Market potential in 6 months or so as well as the above developments and acquisition potential all for a US 200mm MC-nice opportunity,imo..although I'm not a fan of currency differential/foreign sec. holding fees.
A few followers have been posting at IV on this Co. as well.